Germany's Fresenius issues to double equity:
This article was originally published in Clinica
German dialysis company Fresenius plans to double its capital to E102.4 million ($93.4 million) by issuing 10 million new ordinary shares and 10 million non-voting preferred shares. Existing ordinary shareholders will get an extra share, while non-voting preference shareholders get one new preference share for each share held. The move is designed to make Fresenius' shares "even more attractive" to a larger circle of investors, the Bad Homburg company says.